Get started
Author

Chinatsu Makiyama

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
2017 · Toshikazu Moriwaki, Shota Fukuoka, et al. · The Oncologist · 107
PDF
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
2017 · Akitaka Makiyama, Kohei Arimizu, et al. · Gastric Cancer · 63
PDF
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer
2017 · Kotoe Takayoshi, Hitoshi Kusaba, et al. · Cancer Chemotherapy and Pharmacology · 30
PDF
NUT carcinoma of the nasal cavity that responded to a chemotherapy regimen for Ewing’s sarcoma family of tumors: a case report
2018 · Kohei Arimizu, Gen Hirano, et al. · BMC Cancer · 29
PDF
Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
2015 · Gen Hirano, Akitaka Makiyama, et al. · PubMed · 18
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan.
2014 · Taichi Isobe, Keita Uchino, et al. · PubMed · 12
Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab
2025 · Toshihiko Matsumoto, Tatsuki Ikoma, et al. · Scientific Reports · 5
PDF
A retrospective study to compare TAS-102 with TAS-102+BV in advanced colorectal cancer refractory to standard therapy
2018 · Akitaka Makiyama, Satoru Yamaga, et al. · Annals of Oncology · 3
A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy
2018 · Hozumi Kumagai, Hitoshi Kusaba, et al. · Medicine · 3
Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites
2026 · Toshihiko Matsumoto, Soma Sugimoto, et al. · World Journal of Gastrointestinal Oncology · 1
P22-1 Nivolumab combination chemotherapy (NC) for HER2-negative, unresectable, advanced, or recurrent gastric cancer (AGC): A retrospective observational study
2023 · Wakana Chikaishi, Akitaka Makiyama, et al. · Annals of Oncology · 1
PDF
Salvage line CPT-11 after failure of fluoropyrimidine and paclitaxel-based chemotherapy in advanced gastric cancer
2015 · Chinatsu Makiyama, Gen Hirano, et al. · Annals of Oncology · 1
PDF
Efficacy and Safety of Reduced-Dose Chemotherapy Plus Nivolumab in Elderly Advanced Gastric Cancer
2026 · Toshihiko Matsumoto, Souma Sugimoto, et al. · Gastroenterology Insights
P11-3 Efficay and safety of chemotherapy plus nivolumab for advanced gastric cancer with ascites
2024 · T. Matsumoto, C. Makiyama, et al. · Annals of Oncology
PDF
P-171 The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer
2016 · A. Makiyama, K. Arimizu, et al. · Annals of Oncology
Successful treatment with “re-switching” of regorafenib and cetuximab for mCRC patient with liver metastases
2015 · Akitaka Makiyama, Gen Hirano, et al. · Annals of Oncology
Significance of hypersensitivity reactions in the outpatient infusion unit: Retrospective study in JCHO Kyushu hospital
2015 · Kyoko Tomoda, Tsuyoshi Muta, et al. · Annals of Oncology
PDF
Retrospective Study of Treatment with S-1 Alone Or S-1 Plus Cisplatin in Elderly Patients with Advanced Gastric Cancer
2013 · C. Makiyama, T. Kajitani, et al. · Annals of Oncology
PDF
Works count: 18
Citation count: 272
H-index: 6
I10-index: 6
Year
Topic
Type